Anzeige
Meldung des Tages: Lithium ist zurück — und diesmal führen Institutionen den Markt an

Theravance Biopharma Aktie News

Aktie
WKN:  A1137V ISIN:  KYG8807B1068 US-Symbol:  TBPH Branche:  Biotechnologie Land:  USA
17,10 €
+0,00 €
0,00%
12:48:28 Uhr
Depot/Watchlist
Marktkapitalisierung *
782,93 Mio. €
Streubesitz
-
KGV
160,33
Index-Zuordnung
-

Theravance Biopharma News

20.11.25 - PR Newswire
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, ...
19.11.25 - PR Newswire
Theravance Biopharma to Participate in Upcoming Investor Conferences
Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire
10.11.25 - PR Newswire
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
29.10.25 - PR Newswire
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System PR Newswire
27.10.25 - PR Newswire
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 PR Newswire
14.10.25 - PR Newswire
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting PR Newswire
02.09.25 - PR Newswire
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
25.08.25 - PR Newswire
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to ...
12.08.25 - PR Newswire
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
28.07.25 - PR Newswire
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 PR Newswire
23.07.25 - PR Newswire
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire
26.06.25 - PR Newswire
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA PR Newswire
02.06.25 - PR Newswire
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million PR Newswire
13.05.25 - PR Newswire
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire
09.05.25 - PR Newswire
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress PR Newswire
08.05.25 - PR Newswire
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
28.04.25 - PR Newswire
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress PR Newswire
24.04.25 - PR Newswire
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 PR Newswire
07.04.25 - PR Newswire
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting PR Newswire
31.03.25 - PR Newswire
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »